Clinical Trials Directory

We are doing this study to learn more about how brain cell activity guides memory and navigation.

The Endometrial Cancer Molecularly Targeted Therapy Consortium is a multi-institutional alliance that is developing a cancer data and tissue repository. The information in this repository will be used to better understand tumor alterations and cancer biomarkers that can help us develop new therapies and potentially improve survival outcomes for women with endometrial cancer.

In this study, people will get a special shot called a nerve block. It is given in the back of the neck while the person is asleep under general anesthesia. This means they will not feel anything during the procedure.

We are doing this study to keep tabs on the performance of a medical device called TVT Exact. This device is used to help control stress urinary incontinence. We want to know how well this device works long-term in Duke patients who elected to use it.

In this study, everyone receives a medicine called EVOLVE104 through an IV, which means it goes into a vein. This is an open label study, so everyone knows the drug and dose they are getting. Each infusion takes about one hour, and doctors will watch you closely during the infusion and for up to two days after it, especially at the beginning. The first three doses are given one week apart. After that, the doses are given every week or every two weeks in 28 day cycles. Early doses may require staying in the hospital overnight and may start at a lower amount that increases slowly to help your body adjust. During the study, you will have regular checkups, blood tests, heart tests, scans every eight weeks, and eye exams. The study has different stages, including screening, treatment, end of treatment, and long term follow up. Screening can last up to 28 days and includes exams, blood tests, heart tests, eye exams, and scans to make sure you can join the study.